Andros Pharmaceuticals Co (ROCO:6917) EV-to-Revenue : 649.05 (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Andros Pharmaceuticals Co's enterprise value is NT$522.49 Mil. Andros Pharmaceuticals Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.81 Mil. Therefore, Andros Pharmaceuticals Co's EV-to-Revenue for today is 649.05.

The historical rank and industry rank for Andros Pharmaceuticals Co's EV-to-Revenue or its related term are showing as below:

ROCO:6917' s EV-to-Revenue Range Over the Past 10 Years
Min: 322.58 Med: 480.58 Max: 611.48
Current: 649.05

During the past 5 years, the highest EV-to-Revenue of Andros Pharmaceuticals Co was 611.48. The lowest was 322.58. And the median was 480.58.

ROCO:6917's EV-to-Revenue is ranked worse than
93.16% of 1038 companies
in the Biotechnology industry
Industry Median: 7.985 vs ROCO:6917: 649.05

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Andros Pharmaceuticals Co's stock price is NT$20.95. Andros Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.02. Therefore, Andros Pharmaceuticals Co's PS Ratio for today is 997.62.

Andros Pharmaceuticals Co EV-to-Revenue Historical Data

The historical data trend for Andros Pharmaceuticals Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co EV-to-Revenue Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

871.52

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial			-	-	-	-	871.52

Competitive Comparison of Andros Pharmaceuticals Co's EV-to-Revenue

For the Biotechnology subindustry, Andros Pharmaceuticals Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's EV-to-Revenue falls into.

Andros Pharmaceuticals Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Andros Pharmaceuticals Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	522.485	/	0.805
	=	649.05

Andros Pharmaceuticals Co's current Enterprise Value is NT$522.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.81 Mil.

Andros Pharmaceuticals Co (ROCO:6917) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Andros Pharmaceuticals Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	20.95	/	0.021
	=	997.62

Andros Pharmaceuticals Co's share price for today is NT$20.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.02.

Andros Pharmaceuticals Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines